Moderna Announces Permanent Immunity Potential in Vaccine

Moderna Announces Permanent Immunity Potential in Vaccine Making a statement about the vaccine they developed with RNA technology, the US biotech company Moderna announced that there is a permanent immunity potential in the vaccine. New details regarding vaccines developed for use in the treatment of coronavirus are announced. Moderna stated that the latest data on the vaccine study offered persistent immune potential in all age groups, 119 days after the first dose was administered and 90 days after the second dose. “Phase-1 data show that our coronavirus vaccine can provide permanent immunity in all age groups,” said Tal Zaks, Moderna Medical Director, on the company's official website. While the company aims to supply 20 million doses of vaccine in the USA by the end of 2020, it aims to provide 100-125 million doses of vaccines worldwide in the first quarter of 2021. While 85-100 million doses of these vaccines are planned for the USA, the remaining part will be supplied to other countries.